Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

212.45 -0.28 (-0.13%)
Streaming Delayed Price Updated: 1:27 PM EDT, Jun 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 508,236
Open 209.46
Bid (Size) 212.10 (200)
Ask (Size) 212.70 (100)
Prev. Close 212.73
Today's Range 204.16 - 212.45
52wk Range 131.81 - 256.36
Shares Outstanding 139,693,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
From Natera, Inc.
Via Business Wire
News headline image
NWI Management Dumps 42,700 MercadoLibre Shares Worth $82.4 Million ↗
MercadoLibre delivers e-commerce and fintech solutions across Latin America, leveraging an integrated digital ecosystem for regional growth. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
-7.2%
-7.2%
1 Month
+0.4%
+0.4%
3 Month
+2.6%
+2.6%
6 Month
-10.2%
-10.2%
1 Year
+32.2%
+32.2%

More News

Read More
News headline image
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
From Natera, Inc.
Via Business Wire
Natera (NTRA) Q1 Revenue Beat Overshadowed by EPS Miss and Operating Losses ↗
Via Chartmill
News headline image
Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology
From Natera, Inc.
Via Business Wire
News headline image
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World
From Natera, Inc.
Via Business Wire
News headline image
EXPAND Trial of Natera’s Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled
From Natera, Inc.
Via Business Wire
News headline image
1 Mid-Cap Stock with Exciting Potential and 2 That Underwhelm
Via StockStory
News headline image
5 Must-Read Analyst Questions From Natera’s Q1 Earnings Call
Via StockStory
Topics Earnings
News headline image
Why Natera (NTRA) Shares Are Plunging Today
Via StockStory
Topics Artificial Intelligence Economy
News headline image
Natera Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
NTRA Q1 Deep Dive: Robust Volume Growth and Product Expansion Shape Outlook
Via StockStory
News headline image
Natera NTRA Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Natera’s (NASDAQ:NTRA) Q1 CY2026 Sales Top Estimates
Via StockStory
News headline image
Natera Reports First Quarter 2026 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
What To Expect From Natera’s (NTRA) Q4 Earnings
Via StockStory
News headline image
Natera to Report its First Quarter Results on May 7, 2026
From Natera, Inc.
Via Business Wire
News headline image
Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT
From Natera, Inc.
Via Business Wire
News headline image
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
Via StockStory
Topics Artificial Intelligence
News headline image
3 Reasons We’re Fans of Natera (NTRA)
Via StockStory
Topics Stocks
News headline image
Natera, UFP Technologies, Mettler-Toledo, and Viatris Shares Are Soaring, What You Need To Know
Via StockStory
Topics Economy Government Stocks
News headline image
1 Cash-Producing Stock to Own for Decades and 2 That Underwhelm
Via StockStory
News headline image
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma
From Natera, Inc.
Via Business Wire

Frequently Asked Questions

Is Natera, Inc. - Common Stock publicly traded?
Yes, Natera, Inc. - Common Stock is publicly traded.
What exchange does Natera, Inc. - Common Stock trade on?
Natera, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Natera, Inc. - Common Stock?
The ticker symbol for Natera, Inc. - Common Stock is NTRA on the Nasdaq Stock Market
What is the current price of Natera, Inc. - Common Stock?
The current price of Natera, Inc. - Common Stock is 212.45
When was Natera, Inc. - Common Stock last traded?
The last trade of Natera, Inc. - Common Stock was at 06/03/26 01:27 PM ET
What is the market capitalization of Natera, Inc. - Common Stock?
The market capitalization of Natera, Inc. - Common Stock is 29.68B
How many shares of Natera, Inc. - Common Stock are outstanding?
Natera, Inc. - Common Stock has 30B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.